Advertisement

Heart Failure pp 307-317 | Cite as

Mechanical Circulatory Support Part II; Management of Devices After Implantation, Incl. Complications

  • A. L. Meyer
  • I. Netuka
  • M. S. SlaughterEmail author
Chapter
Part of the Cardiovascular Medicine book series (CVM)

Abstract

Post-operative right heart failure after LVAD implantation occurs in 9–20% [1] and is associated with high 30-days mortality [2]. Several options are given to optimize the post-operative right ventricular function. A pulmonary artery catheter is obligate for optimal hemodynamic and volume management. Recommended parameters are CVP < 15 mmHg and PCWP 15–20 mmHg with a mean artery pressure between 70 and 80 mmHg.

References

  1. 1.
    Strueber M, Larbalestier R, Jansz P, Zimpfer D, Fiane AE, Tsui S, Simon A, Schmitto JD, Khaghani A, Wieselthaler GM, et al. Results of the post-market registry to evaluate the HeartWare left ventricular assist system (ReVOLVE). J Heart Lung Transplant. 2014;33(5):486–91.PubMedGoogle Scholar
  2. 2.
    Kormos RL, Teuteberg JJ, Pagani FD, Russell SD, John R, Miller LW, Massey T, Milano CA, Moazami N, Sundareswaran KS, Farrar DJ. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg. 2010;139(5):1316–24.PubMedGoogle Scholar
  3. 3.
    Tedford RJ, Hemnes AR, Russell SD, Wittstein IS, Mahmud M, Zaiman AL, Mathai SC, Thiemann DR, Hassoun PM, Girgis RE, et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail. 2008;1(4):213–9.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Patlolla B, Beygui R, Haddad F. Right-ventricular failure following left ventricle assist device implantation. Curr Opin Cardiol. 2013;28(2):223–33.PubMedGoogle Scholar
  5. 5.
  6. 6.
  7. 7.
  8. 8.
    CE trial HM 3 anticoagulation study protocol.Google Scholar
  9. 9.
    Meyer AL, Malehsa D, Budde U, Bara C, Haverich A, Strueber M. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail. 2014;2(2):141–5.PubMedGoogle Scholar
  10. 10.
    Morgan JA, Paone G, Nemeh HW, Henry SE, Gerlach B, Williams CT, Lanfear DE, Tita C, Brewer RJ. Non-cardiac surgery in patients on long-term left ventricular assist device support. J Heart Lung Transplant. 2012;31(7):757–63.PubMedGoogle Scholar
  11. 11.
    Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, et al. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: executive summary. J Heart Lung Tranplant. 2013;32(2):157–87.Google Scholar
  12. 12.
    Terrovitis JV, Ntalianis A, Kapelios CJ, Vakrou S, Diakos N, Katsaros L, Tsamatsoulis M, Kaldara E, Charitos C, Nanas JN. Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device. Hell J Cardiol. 2015;56(1):20–5.Google Scholar
  13. 13.
    Katz JN, Adamson RM, John R, Tatooles A, Sundareswaran K, Kallel F, Farrar DJ, Jorde UP. Safety of reduced anti-thrombotic strategies in HeartMate II patients: a one-year analysis of the US-TRACE study. J Heart Lung Transplant. 2015;34(12):1542–8.PubMedGoogle Scholar
  14. 14.
  15. 15.
    Riebandt J, Haberl T, Mahr S, Laufer G, Rajek A, Steinlechner B, Schima H, Zimpfer D. Preoperative patient optimization using extracorporeal life support improves outcomes of INTERMACS Level I patients receiving a permanent ventricular assist device. Eur J Cardiothorac Surg. 2014;46(3):486–92. discussion 492PubMedGoogle Scholar
  16. 16.
    Goldstein DJ, Aaronson KD, Tatooles AJ, Silvestry SC, Jeevanandam V, Gordon R, Hathaway DR, Najarian KB, Slaughter MS. Gastrointestinal bleeding in recipients of the HeartWare ventricular assist system. JACC Heart Fail. 2015;3(4):303–13.PubMedGoogle Scholar
  17. 17.
    Draper KV, Huang RJ, Gerson LB. GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. Gastrointest Endosc. 2014;80(3):435–46. e431PubMedGoogle Scholar
  18. 18.
    Wever-Pinzon O, Selzman CH, Drakos SG, Saidi A, Stoddard GJ, Gilbert EM, Labedi M, Reid BB, Davis ES, Kfoury AG, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail. 2013;6(3):517–26.PubMedGoogle Scholar
  19. 19.
    Boyle AJ, Jorde UP, Sun B, Park SJ, Milano CA, Frazier OH, Sundareswaran KS, Farrar DJ, Russell SD. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol. 2014;63(9):880–8.PubMedGoogle Scholar
  20. 20.
    John R, Naka Y, Smedira NG, Starling R, Jorde U, Eckman P, Farrar DJ, Pagani FD. Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial. Ann Thorac Surg. 2011;92(4):1406–13. discussion 1413PubMedGoogle Scholar
  21. 21.
    Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, Conte JV, Naka Y, Mancini D, Delgado RM, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357(9):885–96.Google Scholar
  22. 22.
    Adler SN, Bjarnason I, Metzger YC. New balloon-guided technique for deep small-intestine endoscopy using standard endoscopes. Endoscopy. 2008;40(6):502–5.PubMedGoogle Scholar
  23. 23.
    Meyer AL, Malehsa D, Budde U, Bara C, Haverich A, Strueber M. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail. 2014;2(2):141–5.PubMedGoogle Scholar
  24. 24.
    Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol. 2009;53(23):2162–7.PubMedGoogle Scholar
  25. 25.
    Suarez J, Patel CB, Felker GM, Becker R, Hernandez AF, Rogers JG. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail. 2011;4(6):779–84.PubMedGoogle Scholar
  26. 26.
    Aggarwal A, Pant R, Kumar S, Sharma P, Gallagher C, Tatooles AJ, Pappas PS, Bhat G. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thorac Surg. 2012;93(5):1534–40.PubMedGoogle Scholar
  27. 27.
    Loyada-Rendon RY, Hashim T, Tallaj JA, Acharya D, Holman W, Kirklin J, Pamboukian SV. Octreotide in the management of recurrent gastrointestinal bleed in patients supported by continuous flow left ventricular assist devices. ASAIO J. 2015;61(1):107–9.Google Scholar
  28. 28.
    Hasin T, Topilsky Y, Schirger JA, Li Z, Zhao Y, Boilson BA, Clavell AL, Rodeheffer RJ, Frantz RP, Edwards BS, Pereira NL, Joyce L, Daly R, Park SJ, Kushwaha SS. Changes in renal function after implantation of continuous-flow left ventricular assist devices. J Am Coll Cardiol. 2012;59:26–36.PubMedGoogle Scholar
  29. 29.
    Ootaki C, Yamashita M, Ootaki Y, Kamohara K, Weber S, Klatte RS, Smith WA, Massiello AL, Emancipator SN, Golding LAR, Fukamachi KA. Reduced pulsatility induces periarteritis in kidney: role of the local renin-angiotensin system. J Thorac Cardiovasc Surg. 2008;136:150–8.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH. HeartMate II investigators: advanced heart failure treated with continuous-flowleft ventricular assist device. N Engl J Med. 2009;361:2241–51.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Russell SD, Rogers JG, Milano CA, Dyke DB, Pagani FD, Aranda JM, Klodell CT Jr, Boyle AJ, John R, Chen L, Massey HT, Farrar DJ, Conte JV. HeartMate II clinical investigators: renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation. 2009;120:2352–7.PubMedGoogle Scholar
  32. 32.
    Yoshioka D, Sakaguchi T, Saito S, Miyagawa S, Nishi H, Yoshikawa Y, Fukushima S, Saito T, Daimon T, Ueno T, Kuratani T, Sawa Y. Predictor of early mortality for severe heart failure patients with left ventricular assist device implantation: significance of INTERMACS level and renal function. Circ J. 2012;76:1631–8.PubMedGoogle Scholar
  33. 33.
    Demirozu ZT, Etheridge WB, Radovancevic R, Frazier OH. Results of HeartMate II left ventricular assist device implantation on renal function in patients requiring post-implant renal replacement therapy. J Heart Lung Transplant. 2011;30:182–7.PubMedGoogle Scholar
  34. 34.
    Backes D, van den Bergh WM, van Duijn AL, et al. Cerebrovascular complications of left ventricular assist devices. Eur J Cardiothorac Surg. 2012;42:612–20.PubMedGoogle Scholar
  35. 35.
    Kato TS, Schulze PC, Yang J, et al. Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device. J Heart Lung Transplant. 2012;31:1–8.PubMedGoogle Scholar
  36. 36.
    Najjar SS, Slaughter MS, Pagani FD, et al. An analysis of pump thrombosis events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol. J Heart Lung Transplant. 2014;33:23–34.PubMedGoogle Scholar
  37. 37.
    Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009;373:1632–44.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Willey JZ, Demmer RT, Takayama H, Colombo PC, Lazar RM. Cerebrovascular disease in the era of left ventricular assist devices with continuous flow: risk factors, diagnosis, and treatment. J Heart Lung Transplant. 2014;33(9):878–87.PubMedGoogle Scholar
  39. 39.
    Lampert BC, Eckert C, Weaver S, et al. Blood pressure control in continuous flow left ventricular assist devices: efficacy and impact on adverse events. Ann Thorac Surg. 2014;97:139–46.PubMedGoogle Scholar
  40. 40.
    Morgenstern LB, Hemphill JC 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2010;41:2108–29.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Willey JZ, Gavalas MV, Trinh PN, Yuzefpolskaya M, Reshad Garan A, Levin AP, Takeda K, Takayama H, Fried J, Naka Y, Topkara VK, Colombo PC. Outcomes after stroke complicating left ventricular assist device. J Heart Lung Transplant. 2016.; pii:S1053–2498(16)30067–5Google Scholar
  42. 42.
    Shah P, Mehta VM, Cowger JA, Aaronson KD, Pagani FD. Diagnosis of hemolysis and device thrombosis with lactate dehydrogenase during left ventricular assist device support. J Heart Lung Transplant. 2014;33:102–4.PubMedGoogle Scholar
  43. 43.
    Birschmann I, Dittrich M, Eller T, Wiegmann B, Reininger AJ, Budde U, Strüber M. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices. J Heart Lung Transplant. 2014;33(1):80–7.PubMedGoogle Scholar
  44. 44.
    Netuka I, Sood P, Pya Y, Zimpfer D, Krabatsch T, Garbade J, Rao V, Morshuis M, Marasco S, Beyersdorf F, Damme L, Schmitto JD. Fully magnetically levitated left ventricular assist system for treating advanced HF: a multicenter study. J Am Coll Cardiol. 2015;66(23):2579–89.Google Scholar
  45. 45.
    Gopalan RS, Arabia FA, Noel P, Chandrasekaran K. Hemolysis from aortic regurgitation mimicking pump thrombosis in a patient with a HeartMate II left ventricular assist device: a case report. ASAIO J. 2012;58(3):278–80.PubMedGoogle Scholar
  46. 46.
    Alhosaini H, Jensen BC, Chang PP, Sheridan BC, Katz JN. A novel link between G6PD deficiency and hemolysis in patients with continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2014;33(1):116–7.PubMedGoogle Scholar
  47. 47.
    Interagency Registry for Mechanically Assisted Circulatory Support, National Heart Lung and Blood Institute.Adverse event definitions. Contract Award HHSN268201100025C. Available at: http://www.uab.edu/medicine/intermacs/manual-of-operations/manual-of-operations-dropdown3/appendix-a-adverse-event definitions. Accessed 12 Dec 2013.
  48. 48.
    Katz JN, Jensen BC, Chang PP, Myers SL, Pagani FD, Kirklin JK. A multicenter analysis of clinical hemolysis in patients supported with durable, long-term left ventricular assist device therapy. J Heart Lung Transplant. 2015;34(5):701–9.PubMedGoogle Scholar
  49. 49.
    Shah P, Mehta VM, Cowger JA, Haft JW, Romano MA, Aaronson KD, Pagani FD. Lactate dehydrogenase is superior to serum free hemoglobin as a marker of pump thrombosis in left ventricular assist devices. J Heart Lung Transplant. 2013;32:S37.Google Scholar
  50. 50.
    Cowger JA, Romano MA, Shah P, Shah N, Mehta V, Haft JW, Aaronson KD, Pagani FD. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transplant. 2014;33:35–43.PubMedGoogle Scholar
  51. 51.
    McCarthy FH, Kobrin D, Rame JE, Groeneveld PW, McDermott KM, Atluri P, Acker MA, Desai ND. Increasing frequency of left ventricular assist device exchanges in the United States. Ann Thorac Surg. 2015;100(5):1660–4. discussion 1665PubMedGoogle Scholar
  52. 52.
    Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB. Seventh INTERMACS annual report: 15,000 patient sand counting. J Heart Lung Transplant. 2015;34(12):1495-1504. Ota T, Yerebakan H, Akashi H, Takayama H, Uriel N, Colombo PC, Jorde UP, Naka Y. Continuous-flow left ventricular assist device ex- change: clinical outcomes. J Heart Lung Transplant 2014;33:65–70.PubMedGoogle Scholar
  53. 53.
    Stulak JM, Cowger J, Haft JW, Romano MA, Aaronson KD, Pagani FD. Device exchange after primary left ventricular assist device implanta- tion: indications and outcomes. Ann Thorac Surg. 2013;95:1262–7. discussion 1267PubMedGoogle Scholar
  54. 54.
    Levin AP, Uriel N, Takayama H, Mody KP, Ota T, Yuzefpolskaya M, Colombo PC, Garan AR, Dionizovik-Dimanovski M, Sladen RN, Naka Y, Jorde UP. Device exchange in HeartMate II recipients: long-term out- comes and risk of thrombosis recurrence. ASAIO J. 2015;61:144–9.PubMedGoogle Scholar
  55. 55.
    Soleimani B, Stephenson ER, Price LC, El-Banayosy A, Pae WE. Clinical experience with sternotomy versus subcostal approach for exchange of HeartMate II left ventricular assist device. Ann Thorac Surg. 2015;100(5):1577–80.PubMedGoogle Scholar
  56. 56.
    Ota T, Yerebakan H, Akashi H, Takayama H, Uriel N, Colombo PC, Jorde UP, Naka Y. Continuous-flow left ventricular assist device exchange: clinical outcomes. J Heart Lung Transplant. 2014;33(1):65–70.7.PubMedGoogle Scholar
  57. 57.
    Levin AP, Saeed O, Willey JZ, Levin CJ, Fried JA, Patel SR, Sims DB, Nguyen JD, Shin JJ, Topkara VK, Colombo PC, Goldstein DJ, Naka Y, Takayama H, Uriel N, Jorde UP. Watchful waiting in continuous-flow left ventricular assist device patients with ongoing hemolysis is associated with an increased risk for cerebrovascular accident or death. Circ Heart Fail. 2016;9(5). pii: e002896Google Scholar
  58. 58.
    Hanke JS, Haverich A, Schmitto JD. Exchange of a HeartMate II left ventricular assist device with a HeartMate 3 pump. J Heart Lung Transplant. 2016. pii: S1053–2498(16)30066–3.Google Scholar
  59. 59.
  60. 60.
    Xie A, Phan K, Yan TD. Durability of continuous-flow left ventricular assist devices: a systematic review. Ann Cardiothorac Surg. 2014;3(6):547–56.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Starling RC, Moazami N, Silvestry SC, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370:33–40.PubMedGoogle Scholar
  63. 63.
    Najjar SS, Slaughter MS, Pagani FD, et al. An analysis of pump thrombosis events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol. J Heart Lung Transplant. 2014;33:23–34.PubMedGoogle Scholar
  64. 64.
    Mehra MR, Stewart GC, Uber PA. The vexing problem of thrombosis in long-term mechanical circulatory support. J Heart Lung Transplant. 2014;33:1–11.PubMedGoogle Scholar
  65. 65.
    Soltani S, Kaufmann F, Vierecke J, Kretzschmar A, Hennig E, Stein J, Hetzer R, Krabatsch T, Potapov EV. Design changes in continuous-flow left ventricular assist devices and life-threatening pump malfunctions. Eur J Cardiothorac Surg. 2015;47(6):984–9.PubMedGoogle Scholar
  66. 66.
    Schima H, Stoiber M, Schlöglhofer T, Hartner Z, Haberl T, Zimpfer D. Repair of left ventricular assist device driveline damage directly at the transcutaneous exit site. Artif Organs. 2014;38(5):422–5.PubMedGoogle Scholar
  67. 67.
    Chrysant GS, Horstmanshof DA, Snyder T, Chaffin JS, Elkins CC, Kanaly PJ, Long JW. Successful percutaneous management of acute left ventricular assist device stoppage. ASAIO J. 2010;56(5):483–5.PubMedGoogle Scholar
  68. 68.
    Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015;34(12):1495–504.PubMedGoogle Scholar
  69. 69.
    Hasin T, Marmor Y, Kremers W, Topilsky Y, Severson CJ, Schirger JA, Boilson BA, Clavell AL, Rodeheffer RJ, Frantz RP, Edwards BS, Pereira NL, Stulak JM, Joyce L, Daly R, Park SJ, Kushwaha SS. Readmissions after implantation of axial flow left ventricular assist device. J Am Coll Cardiol. 2013;61(2):153–63.PubMedGoogle Scholar
  70. 70.
    Akhter SA, Badami A, Murray M, Kohmoto T, Lozonschi L, Osaki S, Lushaj EB. Hospital readmissions after continuous-flow left ventricular assist device implantation: incidence, causes, and cost analysis. Ann Thorac Surg. 2015;100:884–9.PubMedGoogle Scholar
  71. 71.
    Stulak JM, Davis ME, Haglund N, Dunlay S, Cowger J, Shah P, Pagani FD, Aaronson KD, Maltais S. Adverse events in contemporary continuous-flow left ventricular assist devices: a multi-institutional comparison shows significant differences. J Thorac Cardiovasc Surg. 2016;151(1):177–89.PubMedGoogle Scholar
  72. 72.
    Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH. HeartMate II investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241–51.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Miller MA, Timothy Baldwin J, Young JB. Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant. 2014;33(6):555–64.PubMedGoogle Scholar
  74. 74.
    Schaffer JM, Allen JG, Weiss ES, Arnaoutakis GJ, Patel ND, Russell SD, Shah AS, Conte JV. Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation. J Heart Lung Transplant. 2011;30(2):164–74.PubMedGoogle Scholar
  75. 75.
  76. 76.
    Hannan MM, Husain S, Mattner F, Danziger-Isakov L, Drew RJ, Corey GR, Schueler S, Holman WL, Lawler LP, Gordon SM, Mahon NG, Herre JM, Gould K, Montoya JG, Padera RF, Kormos RL, Conte JV, Mooney ML. International Society for Heart and Lung Transplantation. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant. 2011;30(4):375–84.PubMedGoogle Scholar
  77. 77.
    Nienaber JJ, Kusne S, Riaz T, Walker RC, Baddour LM, Wright AJ, Park SJ, Vikram HR, Keating MR, Arabia FA, Lahr BD, Sohail MR. Mayo cardiovascular infections study group. Clinical manifestations and management of left ventricular assist device-associated infections. Clin Infect Dis. 2013;57(10):1438–48.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Tong MZ, Smedira NG, Soltesz EG, Starling RC, Koval CE, Porepa L, Moazami N. Outcomes of heart transplant after left ventricular assist device specific and related infection. Ann Thorac Surg. 2015;100(4):1292–7.PubMedGoogle Scholar
  79. 79.
    Chinn R, Dembitsky W, Eaton L, Chillcott S, Stahovich M, Rasmusson B, Pagani F. Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J. 2005;51(4):461–70.PubMedGoogle Scholar
  80. 80.
    Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, Bashore T, Corey GR. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633–8.PubMedGoogle Scholar
  81. 81.
    Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1–45.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, Bolger AF, Steckelberg JM, Baltimore RS, Fink AM, O’Gara P, Taubert KA. American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435–86.PubMedGoogle Scholar
  83. 83.
    Stulak JM, Romans T, Cowger J, Romano MA, Haft JW, Aaronson KD, Pagani FD. Delayed sternal closure does not increase late infection risk in patients undergoing left ventricular assist device implantation. J Heart Lung Transplant. 2012;31(10):1115–9.PubMedGoogle Scholar
  84. 84.
    Kimura M, Nishimura T, Kinoshita O, Okada S, Inafuku H, Kyo S, Ono M. Successful treatment of pump pocket infection after left ventricular assist device implantation by negative pressure wound therapy and omental transposition. Ann Thorac Cardiovasc Surg. 2014;20(Suppl):842–5.PubMedGoogle Scholar
  85. 85.
    Shafii AE, Chamogeorgakis TP, Gonzalez-Stawinski G. Omental flap transposition with intra-abdominal relocation for LVAD pump-pocket infection. J Heart Lung Transplant. 2011;30(12):1421–2.PubMedGoogle Scholar
  86. 86.
    Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, Ewald GA, Sundareswaran KS, Farrar DJ, Slaughter MS. HeartMate II clinical investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5(2):241–8.PubMedGoogle Scholar
  87. 87.
    John R, Aaronson KD, Pae WE, Acker MA, Hathaway DR, Najarian KB, Slaughter MS, HeartWare Bridge to Transplant ADVANCE Trial Investigators. Drive-line infections and sepsis in patients receiving the HVAD system as a left ventricular assist device. J Heart Lung Transplant. 2014;33(10):1066–73.PubMedGoogle Scholar
  88. 88.
    Goldstein DJ, Naftel D, Holman W, Bellumkonda L, Pamboukian SV, Pagani FD, Kirklin J. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant. 2012;31(11):1151–7.PubMedGoogle Scholar
  89. 89.
    Dean D, Kallel F, Ewald GA, Tatooles A, Sheridan BC, Brewer RJ, Caldeira C, Farrar DJ, Akhter SA, SSI Registry Investigators. Reduction in driveline infection rates: results from the HeartMate II Multicenter Driveline Silicone Skin Interface (SSI) Registry. J Heart Lung Transplant. 2015;34(6):781–9.PubMedGoogle Scholar
  90. 90.
    Singh A, Russo MJ, Valeroso TB, Anderson AS, Rich JD, Jeevanandam V, Akhter SA. Modified HeartMate II driveline externalization technique significantly decreases incidence of infection and improves long-term survival. ASAIO J. 2014;60(6):613–6.PubMedGoogle Scholar
  91. 91.
    Schibilsky D, Benk C, Haller C, Berchtold-Herz M, Siepe M, Beyersdorf F, Schlensak C. Double tunnel technique for the LVAD driveline: improved management regarding driveline infections. J Artif Organs. 2012;15(1):44–8.PubMedGoogle Scholar
  92. 92.
    Fleissner F, Avsar M, Malehsa D, Strueber M, Haverich A, Schmitto JD. Reduction of driveline infections through doubled driveline tunneling of left ventricular assist devices. Artif Organs. 2013;37(1):102–7.PubMedGoogle Scholar
  93. 93.
    Baronetto A, Centofanti P, Attisani M, Ricci D, Mussa B, Devotini R, Simonato E, Rinaldi M. A simple device to secure ventricular assist device driveline and prevent exit-site infection. Interact Cardiovasc Thorac Surg. 2014;18(4):415–7.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Cagliostro B, Levin AP, Fried J, Stewart S, Parkis G, Mody KP, Garan AR, Topkara V, Takayama H, Naka Y, Jorde UP, Uriel N. Continuous-flow left ventricular assist devices and usefulness of a standardized strategy to reduce drive-line infections. J Heart Lung Transplant 2015. S1053–2498(15)01309-1.Google Scholar
  95. 95.
    Raymond AL, Kfoury AG, Bishop CJ, Davis ES, Goebel KM, Stoker S, Selzman CH, Clayson SE, Smith H, Cowley CG, Alharethi R, Budge D, Reid BB. Obesity and left ventricular assist device driveline exit site infection. ASAIO J. 2010;56(1):57–60.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.University Department for Cardiac SurgeryLeipzig Heart CenterLeipzigGermany
  2. 2.Institute for Clinical and Experimental MedicinePragueCzech Republic
  3. 3.Department of Cardiovascular and Thoracic SurgeryUniversity of LouisvilleLouisvilleUSA

Personalised recommendations